TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25500486
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets administered orally
Study: 25500486
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets administered via nasogastric tube
Study: 25500486
Drug: Whole ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole ticagrelor tablets administered orally
Study: 25500486
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets (both methods)
Study: 19660002
Drug: Udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 200 mg oral dose under fasting conditions
Study: 19660002
Drug: Udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 200 mg oral dose after a low-fat meal
Study: 19660002
Drug: Udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 200 mg oral dose after a high-fat meal
Study: 15462701
Drug: Symbicort adjustable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort adjustable maintenance dosing plan (SAMD) - budesonide/formoterol 1-4 inhalations twice daily depending on symptoms
Study: 15462701
Drug: Symbicort fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort fixed dosing - 2 inhalations twice daily
Study: 9757853
Drug: Hydrocortisone (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for approximately 12 weeks)
Study: 7818065
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with intravenous pethidine
Study: 7818065
Drug: Nurse-controlled pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-controlled pethidine infusions
Study: 2967622
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg Zoladex
Study: 2967622
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg Zoladex
Study: 2967622
Drug: 3.6 mg
Normalized name: menthol 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg Zoladex
Study: 29544738
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (100 mg for ages 2-11, 200 mg for ages 12-17)
Study: 26354560
Drug: Blood Volume
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Volume Monitoring (BVM) treatment
Study: 26354560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BVM treatment)
Study: 22527264
Drug: Human rights‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human rights‐based intervention approach with four dialogical meetings focused on medication intake scenes
Study: 20184444
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of lornoxicam
Study: 19032138
Drug: CC (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (current care)
Study: 17157780
Drug: Oxytrex (oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytrex (oxycodone + ultralow-dose naltrexone) bid
Study: 10681282
Drug: Potato chips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato chips containing 40 g of olestra per day
Study: 3301923
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream once daily
Study: 3301923
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream twice daily
Study: 29534134
Drug: Tissue-level implants
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-level implants restored with platform matching (control group)
Study: 29534134
Drug: Bone-level implants
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-level implants restored with platform switching (test group)
Study: 25201794
Drug: SSI reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSI reduction bundle (prohibition of razors, chlorhexidine-alcohol use, correct timing of prophylactic antibiotics)
Study: 25201794
Drug: Correct timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct timing of preoperative prophylactic antibiotics
Study: 19349870
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lopinavir-ritonavir and 2 nucleosides)
Study: 12399672
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (potent topical steroids + 20% azelaic acid cream)
Study: 12399672
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid cream monotherapy
Study: 18653145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caloric restriction and physical exercise with pharmacological treatment
Study: 7660761
Drug: 2‐h blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐h blood glucose value of 8.0 to 8.9 mmol/l
Study: 7660761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2‐h blood glucose value < 8.0 mmol/l)
Study: 327948
Drug: Erbium 169
Normalized name: erbium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium 169 injection (+prednisolone acetate)
Study: 327948
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (+prednisolone acetate)
Study: 31081712
Drug: Er;Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er;Cr:YSGG laser treatment at 3.75 W power and 15 Hz frequency for 4 min
Study: 31081712
Drug: Hydrofluoric (HF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrofluoric (HF) acid treatment
Study: 31081712
Drug: L1S treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L1S treatment
Study: 31081712
Drug: L2D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L2D treatment
Study: 31081712
Drug: L1D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L1D treatment
Study: 31081712
Drug: L2S treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L2S treatment
Study: 19506377
Drug: Unsafe injecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsafe injecting practices (syringe‐mediated drug sharing)
Study: 16884321
Drug: FBT administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT administered as four 100 microg tablets simultaneously
Study: 16884321
Drug: FBT administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT administered as one 400 microg tablet
Study: 7571476
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg or 8 mg administered once a day)
Study: 7571476
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of perindopril with hydrochlorothiazide
Study: 7571476
Drug: Perindopril (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (monotherapy and combination)
Study: 2153736
Drug: Topical 15%
Normalized name: urea topical 15% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 15% idoxuridine in dimethyl sulfoxide
Study: 2153736
Drug: 80% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% DMSO control solution
Study: 2153736
Drug: 2% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% DMSO control solution
Study: 30326318
Drug: Biographical suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biographical suspension concept
Study: 18319227
Drug: LPC infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPC infusions
Study: 6487462
Drug: Cyclosidimine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosidimine 2.5 mg
Study: 6487462
Drug: Cyclosidimine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosidimine 5.0 mg
Study: 6487462
Drug: Cyclosidimine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosidimine 7.5 mg
Study: 26653112
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU daily vitamin D3
Study: 25347898
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (conventional chemotherapy)
Study: 22925288
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) solution (0.2% two-fold diluted MucoUp)
Study: 18477422
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L‐AMB)
Study: 15807739
Drug: Isotretinoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (1 mg/kg/day) + Vitamin E (800 IU/day)
Study: 15807739
Drug: Isotretinoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (1 mg/kg/day)
Study: 2181312
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ivermectin (21.3 +/- 0.7 micrograms per kilogram; n = 13)
Study: 2181312
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ivermectin (126.2 +/- 3.7 micrograms per kilogram; n = 13)
Study: 2181312
Drug: Diethylcarbamazine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (6 mg per kilogram per day for 12 days preceded by 3 mg per kilogram for 1 day; n = 14)
Study: 31624364
Drug: Hepcidin cutoff
Normalized name: Hepcidin-25
DrugBank: Hepcidin-25 (DB19226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepcidin cutoff <4.3 µg/L
Study: 31624364
Drug: Baseline hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline hemoglobin >110 g/L
Study: 31624364
Drug: Baseline hepcidin
Normalized name: Hepcidin-25
DrugBank: Hepcidin-25 (DB19226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline hepcidin >1.6 µg/L
Study: 23305245
Drug: Trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 200 mg twice daily from day 5 to 10
Study: 21557754
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g of dentifrice
Study: 21557754
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of dentifrice
Study: 18461392
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of 0.1 ml 1% acetylcholine in group A
Study: 9754775
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg plus Amoxicillin 1000 mg b.i.d (OA)
Study: 9754775
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and Placebo b.i.d (OP)
Study: 7826832
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) - total dose of 1500 mg given over 3 days
Study: 18454214
Drug: 10 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg-1 ketamine 5%
Study: 16418156
Drug: Nerve gliding
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve gliding exercises combined with conservative treatment
Study: 16418156
Drug: Static volar
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static volar wrist splints and conservative treatment
Study: 1607432
Drug: Chewable preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable preparation containing chlorhexidine
Study: 1607432
Drug: Xylitol control
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol control tablets
Study: 3984878
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment) in patients with reperfusion
Study: 2451713
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by definitive treatment (arm A)
Study: 24584605
Drug: MgCaCO3 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCaCO3 (100 mg calcium, 85 mg magnesium per tablet)
Study: 24584605
Drug: CaCO3 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 (200 mg calcium per tablet)
Study: 24379009
Drug: Beef lunch
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef lunch (3-oz, 3 times weekly for 16 weeks)
Study: 24379009
Drug: Non-beef lunch
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-beef lunch (3-oz, 3 times weekly for 16 weeks)
Study: 21257028
Drug: Malleable protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malleable protein matrix (MPM) 2 × 15 g/d
Study: 18790543
Drug: Sulfotanshinone Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfotanshinone Sodium Injection (SSI) 60 mg combined with a loading dose of 300 mg aspirin and a maintenance dose of 100 mg of aspirin plus baseline therapy
Study: 18790543
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg loading dose and 100 mg maintenance dose) plus baseline therapy
Study: 16446121
Drug: Pregabalin as
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin as add-on therapy
Study: 12232545
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of agomelatine
Study: 7761292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavior modification and mutual goal setting
Study: 2175584
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg perindopril
Study: 373990
Drug: Haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5 mg twice daily
Study: 373990
Drug: Diazepam 2
Normalized name: diazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 2 mg three times daily
Study: 31381147
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg twice daily on days 2‐21 every 3 weeks for up to 120 weeks combined with carboplatin and paclitaxel.
Study: 29298726
Drug: BMAC-PRP injection
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC-PRP injection
Study: 25394847
Drug: Di'ao Xin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di'ao Xin Xue Kang (XXK) capsule
Study: 25394847
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen (CDS) tablet
Study: 22842953
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 0.075 % 3 times daily for 6 weeks
Study: 20884122
Drug: Praziquantel 75
Normalized name: METRONIDAZOLE 250 mg in 2 g / PRAZIQUANTEL 75 mg in 2 g TOPICAL POWDER [API General Cure]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 75 mg/kg
Study: 18172274
Drug: Fenretinide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (200 mg/day orally for 12 months)
Study: 10836286
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg in the morning and evening, increased to 75 mg twice daily after 4 weeks
Study: 10836286
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg in the morning and placebo in the evening, increased to 20 mg twice daily after 4 weeks
Study: 8925479
Drug: Argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon green laser (AGL) treatment
Study: 8925479
Drug: Krypton red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton red laser (KRL) treatment
Study: 8925479
Drug: Both AGL
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both AGL and KRL treatments
Study: 1806404
Drug: H1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1 antagonist (chlorpheniramine 4 mg)
Study: 6761370
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide orally daily
Study: 6761370
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg slow-release furosemide orally daily
Study: 27842565
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (parenteral morphine at 0.1 mg/kg)
Study: 8837185
Drug: Single-injection femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection femoral 3-in-1 nerve block with 20 mL 0.5% bupivacaine with 1:200,000 epinephrine
Study: 1360803
Drug: Alfentanil 5
Normalized name: alfentanil 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 5 micrograms/kg bolus followed by normal saline infusion
Study: 1360803
Drug: Esmolol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 500 micrograms/kg bolus followed by esmolol 300 micrograms/kg/min infusion
Study: 1360803
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline bolus followed by normal saline infusion
Study: 6386007
Drug: Nifedipine (NI)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NI) 5, 10, 20 mg
Study: 6386007
Drug: Acebutolol (AC)
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acebutolol (AC) 200 mg
Study: 6386007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NI (10 mg three times a day) and AC (200 mg three times a day)
Study: 15752374
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg single-dose pitavastatin in Child-Pugh grade A
Study: 15752374
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg single-dose pitavastatin in Child-Pugh grade B
Study: 2971506
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral pills, progestogen‐only oral pills, vaginal ring
Study: 20420959
Drug: Abdominal draw-in
Normalized name: Drawing Salve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal draw-in manoeuvre in combination with ankle dorsiflexion
Study: 19045963
Drug: Coping-oriented couples
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping-oriented couples therapy (COCT)
Study: 15914517
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin (Apo-warfarin)
Study: 12971525
Drug: HIV vaccine-related
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine-related research protocols
Study: 1346963
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta 2-agonists (higher doses)
Study: 1346963
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of inhaled beta 2-agonists
Study: 1346963
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (additional therapy)
Study: 1346963
Drug: Novel longer-acting
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel longer-acting inhaled beta 2-agonists (salmeterol and formoterol)
Study: 6497569
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg twice a day for two weeks)
Study: 29488154
Drug: Fasiglifam (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam (25 mg oral dose)
Study: 25584315
Drug: PRF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF gel (experimental group I)
Study: 25584315
Drug: PRF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF gel and PRF membrane (experimental group II)
Study: 22449332
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with darbepoetin and G-CSF (n = 41), G-CSF was treated for 3 days at a dose of 10 μg/kg/day, plus a single intravenous injection of 4.5 μg/kg of darbepoetin after coronary angioplasty.
Study: 22449332
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone (n = 19), treated for 3 days at a dose of 10 μg/kg/day.
Study: 20807664
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg, twice-daily, 7 doses)
Study: 20807664
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 IU, once-daily, 4 doses)
Study: 20807664
Drug: Ximelagatran (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (24 mg, twice-daily, 7 doses)
Study: 15800321
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A)
Study: 15800321
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)
Study: 8594122
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) codeine (277 ± 77 mg daily, given every 12 hr)